Heteroaromatic compounds as BTK inhibitors
US-9975882-B2 · May 22, 2018 · US
Heteroaromatic compounds as BTK inhibitors
US10875852B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10875852-B2 |
| Application number | US-201816160048-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 15, 2018 |
| Priority date | Aug 10, 2012 |
| Publication date | Dec 29, 2020 |
| Grant date | Dec 29, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from the group consisting of: 2. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 4. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 5. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 6. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 7. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 8. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 9. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 10. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 12. A method of treating a disease chosen from rheumatoid arthritis, systemic lupus erythromatosis, scleroderma, asthma, allergic rhinitis, allergic eczema, B cell lymphoma, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, ankylosing spondylitis and uveitis, comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a carbon chain containing alicyclic rings · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
containing three or more hetero rings · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10875852B2 cover?
- The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).